Project BioShield, a $5.6 billion, 10-year package to finance the development and stockpiling of pharmaceutical defenses against bioterrorism, passed the House 421-2. It is pending in the Senate. The program would provide incentives for drug manufacturers to research and develop vaccines and antidotes against smallpox, Ebola and other biological agents. The bill also would speed the Food and Drug Administration approval process for such drugs and allow the federal government to distribute unapproved products in emergencies. -- by Tony Fong
Bioterrorism bill passes House, awaits Senate vote
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.